ExpreS2ion Biotech Holding AB Total Assets
ExpreS2ion Biotech Holding AB total assets. Based on the latest financial reports, ExpreS2ion Biotech Holding AB (EXPRS2) holds total assets worth Skr50.40 Million SEK (≈ $5.42 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see EXPRS2 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of ExpreS2ion Biotech Holding AB (2013–2025)
Total assets of ExpreS2ion Biotech Holding AB from 2013 to 2025. This chart illustrates how ExpreS2ion Biotech Holding AB's total assets have evolved over time, based on quarterly financial data. See EXPRS2 live share price for real-time trading data and today's change.
ExpreS2ion Biotech Holding AB - Asset Composition Analysis
ExpreS2ion Biotech Holding AB Total Assets Breakdown (December 2025)
ExpreS2ion Biotech Holding AB total assets breakdown as of December 2025. ExpreS2ion Biotech Holding AB's total assets of Skr50.40 Million consist of 88.4% current assets and 11.6% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 73.0% |
| Accounts Receivable | Skr9.97 Million | 15.3% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr465.00K | 0.7% |
| Intangible Assets | Skr1.50 Million | 2.3% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how ExpreS2ion Biotech Holding AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ExpreS2ion Biotech Holding AB (EXPRS2) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ExpreS2ion Biotech Holding AB's current assets represent 88.4% of total assets in 2025, an increase from 74.1% in 2013.
- Cash Position: Cash and equivalents constituted 73.0% of total assets in 2025, up from 3.3% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 15.3% of total assets.
ExpreS2ion Biotech Holding AB Competitors by Total Assets
Key competitors of ExpreS2ion Biotech Holding AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
ExpreS2ion Biotech Holding AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.87 | 2.60 | 11.83 |
| Quick Ratio | 1.87 | 2.60 | 13.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr20.05 Million | Skr44.26 Million | Skr112.17 Million |
ExpreS2ion Biotech Holding AB - Advanced Valuation Insights
This section examines the relationship between ExpreS2ion Biotech Holding AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.53 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -37.7% |
| Total Assets | Skr65.11 Million |
| Market Capitalization | $1.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values ExpreS2ion Biotech Holding AB's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ExpreS2ion Biotech Holding AB's assets decreased by 37.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ExpreS2ion Biotech Holding AB (2013–2025)
The table below shows the annual total assets of ExpreS2ion Biotech Holding AB from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr65.11 Million ≈ $7.01 Million |
-37.71% |
| 2024-12-31 | Skr104.53 Million ≈ $11.25 Million |
+32.84% |
| 2023-12-31 | Skr78.69 Million ≈ $8.47 Million |
-42.71% |
| 2022-12-31 | Skr137.36 Million ≈ $14.78 Million |
-9.60% |
| 2021-12-31 | Skr151.96 Million ≈ $16.35 Million |
+27.85% |
| 2020-12-31 | Skr118.86 Million ≈ $12.79 Million |
+535.37% |
| 2019-12-31 | Skr18.71 Million ≈ $2.01 Million |
-10.72% |
| 2018-12-31 | Skr20.95 Million ≈ $2.25 Million |
+21.58% |
| 2017-12-31 | Skr17.23 Million ≈ $1.85 Million |
-29.98% |
| 2016-12-31 | Skr24.61 Million ≈ $2.65 Million |
+501.51% |
| 2015-12-31 | Skr4.09 Million ≈ $440.39K |
-25.35% |
| 2014-12-31 | Skr5.48 Million ≈ $589.96K |
+33.48% |
| 2013-12-31 | Skr4.11 Million ≈ $441.98K |
-- |
About ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vacci… Read more